巴西边境猫源孢子丝菌病治疗失败与伊曲康唑MIC升高无关
研究在巴西、巴拉圭、阿根廷三国边境地区2021-2023年从猫抗真菌治疗前分离108株Sporothrix brasiliensis,主要临床表现为播散性皮肤孢子丝菌病(61%),且为唯一导致孢子丝菌病相关死亡(61%)的临床类型。对9种抗真菌药进行菌丝相和酵母相药敏试验,多数药物MIC水平低,菌丝相MIC高于酵母相,尤其伏立康唑和艾沙康唑;结论认为临床表现差异与死亡率差异并非由伊曲康唑MIC升高所致。
要点
- 猫源S. brasiliensis感染以播散性皮肤型为主,该型与孢子丝菌病相关死亡相关。
- 分离株多数抗真菌药MIC低,菌丝相MIC高于酵母相。
- 治疗失败不能仅归因于伊曲康唑MIC升高。
核心结论
- 孢子丝菌病的不同临床表现和死亡率差异并非由伊曲康唑MIC升高引起。
研究设计与样本
- 2021-2023年在巴西、巴拉圭、阿根廷三国边境地区,从猫抗真菌治疗前分离108株S. brasiliensis。
- 对9种抗真菌化合物进行药敏试验,评估菌丝相和酵母相。
主要发现
- 主要临床表现为播散性皮肤孢子丝菌病(61%),且是唯一导致孢子丝菌病相关死亡(61%)的临床类型。
- 多数抗真菌药MIC水平低,但菌丝相MIC高于酵母相,尤其伏立康唑和艾沙康唑。
临床怎么用
- 猫源孢子丝菌病治疗失败时,应结合临床表现与药敏结果综合评估,不宜仅凭伊曲康唑MIC判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cat-transmitted sporotrichosis caused by Sporothrix brasiliensis is an emerging zoonosis in Latin America. Because treatment of feline sporotrichosis is often not effective, we sought to determine whether treatment failure results from S. brasiliensis strains that have existing elevated MICs for itraconazole, the primary treatment for this disease. During 2021-2023 at the triple border region of Brazil, Paraguay, and Argentina, 108 S. brasiliensis strains were isolated from felines before antifungal treatment. The main clinical manifestation was cutaneous disseminated sporotrichosis (61%), which was the only form resulting in sporotrichosis-induced deaths (61%). We conducted antifungal susceptibility testing for 9 antifungal compounds, evaluating for both mycelial and yeast phases. MIC levels were low for most antifungal agents but were higher in the mycelial phase than in the yeast phase, especially for voriconazole and isavuconazole. We conclude that the varying clinical manifestations of sporotrichosis and large differences in mortality rates were not caused by elevated itraconazole MICs.
引用
- do Prado CM, Spruijtenburg B, Razzolini E, et al. Sporothrix brasiliensis Treatment Failure without Initial Elevated Itraconazole MICs in Felids at Border of Brazil. Emerg Infect Dis. 2025. PMID: 40867021. doi:10.3201/eid3109.250156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。